| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2000;35:621.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
From Dipartimento Cardiotoracico (R.P., G.D., M.M.), Laboratorio Microcircolatorio (E.M.), Medicina Interna, Azienda Ospedaliera, Universita di Pisa, Italy.
Correspondence to Dr Roberto Pedrinelli, Dipartimento Cardiotoracico, Università di Pisa, 56100 Pisa, Italy. E-mail r.pedrinelli{at}int.med.unipi.it
| Abstract |
|---|
|
|
|---|
Key Words: calcium antagonists angiotensin-converting enzyme inhibitors blood flow vasoconstriction hypertension, essential
| Introduction |
|---|
|
|
|---|
To test this hypothesis, we evaluated the relation between changes in postural skin vasomotion and objective measures of ankle swelling during treatment with graded doses of amlodipine, a dihydropyridine CCB.10 On the basis of previous reports of reduced ankle swelling during association therapy with angiotensin-converting enzyme inhibitors (ACEIs),11 12 we evaluated those parameters also during amlodipine treatment combined with enalapril, an ACEI.13 Skin blood flow was measured with the use of laser Doppler flowmetry (LDF), a noninvasive method that registers the sudden changes evoked by posture1 5 14 without entailing local heating of skin, injection, trauma, or venous occlusion, all of which may disturb local vasomotor reflexes. Fluid extravasation was indirectly assessed by measuring changes in leg weight by use of the Archimedes principle to measure water displacement induced by immersion of the leg.
| Methods |
|---|
|
|
|---|
Experimental Protocol
The studies were performed between 2 and 4 PM and
2 hours after the last food, drink, or smoking. Drugs were taken at
approximately 8 AM, and measurements were obtained 6 to 8
hours from the last dosing. Patients were at ease with the medical
staff and lay supine for
30 minutes in a quiet, climatized room
(22° to 24°C) at constant barometric pressure (range 756 to
768 mm Hg) and humidity (range 35% to 41%).
The general structure of the study consisted of measurement of LDF, leg weight, and blood pressure (BP) (1) at baseline, (2) after 4-week active treatment (see below), and (3) after 2-week drug withdrawal to evaluate recovery. Three active treatment protocols were performed.
Series 1 (n=10, age 54±6 years)
To characterize the dose-response profile of microvascular and
fluid parameters to amlodipine, the drug was started at 5
mg UID for 2 weeks, increasing the dosage to 10 mg UID during
the final 2 weeks.
Series 2 (n=10, age 58±9 years)
The interaction between calcium channel blockade and
angiotensin-converting enzyme inhibition was assessed by
adding amlodipine (10 mg UIDx2 weeks) in patients who received
enalapril (20 mg UID) for the preceding 2 weeks.
Series 3 (n=8, age 58±7 years)
To evaluate the pattern of response to enalapril at different
doses, a third group of patients was given 10 mg UID enalapril during
the first 2 weeks and 20 mg UID enalapril during the final 2 weeks.
Experimental Methods
Laser Doppler Flowmetry
Skin blood flow was recorded with the use of a laser
Doppler flowmeter (Periflux 4001 Master, Perimed Ltd). The device
contains a solid-state, low-power diode laser (1 mW at the probe tip,
wavelength 780 nm) that delivers a laser light to a cutaneous surface
of
1 mm2 at a depth of
1 mm
through flexible, graded-index, fiberoptic light guides. The laser
light strikes moving red blood cells and is reflected with a shift in
frequency, whereas nonmoving structures cause no shift in
frequency.14 The reflected light is guided from the tissue
surface through a second fiberoptic light guide, mixed, and
analyzed in real-time by an analogue processor that provides a
continuous output of the instantaneous mean Doppler frequency in
the photocurrent identified by a square-law detector; the digitized
signal was fed into a computer for on-line and off-line
analyses. Before each study, the instrument was made null for a
condition of no flow by placing the laser probe in the calibration clip
on a surface containing no mobile structures and calibrated into a
colloidal suspension of latex particles moving by brownian motion.
Biological zero (ie, the laser Doppler flux recorded under
no-flow conditions) was not subtracted because the precise nature of
this measurement is still undetermined.15 16 Time-constant
and sampling frequency were set at 0.03 seconds and 16 Hz,
respectively. Double-sided adhesive disks were attached to the probes,
which then were applied to the skin of the dorsal surface (first
intermetatarsal space) of the right foot and left foot, an anatomic
region characterized by predominance of precapillary
arterioles17 under control of the intrinsic myogenic
tone.3 18 Therefore LDF at this site reflects mainly
nutritional capillary blood flow,18 which is to a large
extent independent of sympathetic stimuli.7 18
Results (expressed in perfusion units, PU, were 1 PU equals 10 mV measured on the analogue output) were computer-derived, smoothed averages (Perisoft, Perimed Ltd) of skin blood flow recordings during the 2 minutes preceding foot lowering (leg dangling 50 cm below the heart level) and at the 9th and 10th minutes of foot dependency, when the parameter was invariably constant in all patients. Data measured at the heart (H) level and during dependency (D) were used to calculate percent postural changes [(H-D)/Hx100] as a measure of postural vasoconstriction. Intraindividual variability of the method as performed in our laboratory has been reported.7
Leg Weight
Leg weight was measured immediately after the LDF session with
patients sitting comfortably on a chair. The right and left limbs were
consecutively immersed up to the inner tibial tuberosity in a Plexiglas
cube that contained lukewarm water (36° to 37°C) to avoid sudden
vasoconstrictor responses. The entire water volume displaced by the
maneuver dripped into a container set on a kitchen scale, thus allowing
accurate (within 5 g) and reproducible (average variation
coefficient 0.8%, n=5 determinations in 5 normal subjects)
measurements.
Blood Pressure
SBP, diastolic BP (DBP), and mean BP (MBP,
diastolic+1/3 pulse pressure) were measured with the use of
an automated oscillometric device (NIBP KO 7267.004, Kontron
Instruments) throughout the study sessions.
Statistics
LDF and limb weight at the right and left sides were averaged.
BP values were the average of
10 determinations. Descriptive
statistics were medians and interquartile range for skewed data and
mean±SD values otherwise. Statistical analysis was based on
Wilcoxons signed-rank test for paired comparisons or
Mann-Whitney test for 2-sample comparisons. A value of
P<0.05 was the limit for statistical significance.
| Results |
|---|
|
|
|---|
|
|
|
Laser Doppler Flowmetry
Resting and dependent skin flow increased dose dependently during
amlodipine and recovered after drug withdrawal (Table 1).
Postural vasoconstriction was blunted (P=0.006 versus
baseline) only at the 10-mg UID dose because of a lesser decrease in
dependent flow (Table 1 and Figure 1, left).
|
Microvascular parameters did not change during enalapril (Tables 2 and 3). Postural vasoconstriction was significantly blunted (P=0.03 versus baseline) by 10 mg UID amlodipine, even in enalapril-pretreated patients (Table 3 and Figure 2, left). The amount of inhibition induced by the CCB given alone or in combination did not differ (compare Figure 1 with Figure 2, left).
|
Leg Weight
No patient developed clinical evidence of ankle and/or pretibial
pitting edema. Amlodipine increased leg weight by a median of 80 (68) g
(P=0.006 versus baseline) at 5 mg and by an additional
68 g (65, P=0.059 versus 5 mg) at 10 mg, a cumulative
increment of 136 g (range 40 to 230, P=0.006 versus
baseline). Weight returned toward normal after drug withdrawal (Table 1 and Figure 1, right).
Leg weight did not change during enalapril (Tables 2 and 3) and increased when 10 mg UID amlodipine was added in enalapril-pretreated patients (Table 3 and Figure 2, right).
Weight gains during amlodipine (10 mg UID) with enalapril (20 mg UID) treatment were comparable to those observed during amlodipine monotherapy at one half that dosage [60 (90) versus 80 (68) g, respectively].
Blood Pressure
Amlodipine and enalapril decreased SBP, DBP, or both (Tables 1 and 2) without a dose-dependent relation. When the 2
drugs were combined (Table 3), BP dropped additively (mean
percent MBP decrement: 10 mg UID amlodipine and 20 mg UID enalapril
combined, 18%; 10 mg UID amlodipine, 13%; and 20 mg UID enalapril,
7%).
Correlations
The correlation between the intraindividual increments in leg
weight and the decrements in postural vasoconstriction was not
statistically significant, either in the overall group
(r=-0.31, P=0.17, n=20) or in the subgroups of
patients treated with amlodipine per se (r=-0.30,
P=0.36, n=10) or combined with enalapril
(r=-0.12, P=0.7, n=10) (Figure 3).
|
| Discussion |
|---|
|
|
|---|
1-adrenoceptor
blockers and angiotensin AT-1 receptor blockers such as
doxazosin and losartan, respectively, were ineffective on
cutaneous microcirculation.7 It is more probable that
blunted postural vasoconstriction by CCBs reflected modulation of
calcium fluxes24 maintaining myogenic tone, an
extracellular calcium-dependent process25 involved in skin
blood flow autoregulation.3 Our findings also show
dose-dependent limb weight gains during administration of amlodipine,
an interesting finding that indicates that dependent edema should not
be seen as an occasional adverse event of CCBs, either
dihydropyridine9 or no
dihydropyridine (eg, see References 26 and 2726 27 ), but rather the
extreme phenotype of a highly consistent
pharmacological effect. In the context of our specific aims, though,
the main outcome of the study was to show coexistence of dependent
fluid extravasation with preserved postural control of skin blood flow
by 5 mg UID amlodipine. Therefore net extravascular fluid shifts may
occur independent from any interference with postural reflex skin
vasoconstriction, in line with the knowledge about the multifactorial
control of capillary fluid filtration and Starlings
equilibrium.28 However, preserved autoregulation during
the 5-mg amlodipine dosing probably prevented additional
interstitial edema accumulation in the dependent limb
because limb weight showed further gains when postural vasomotion was
impaired by a higher dose of the drug. This plausible conclusion,
supported by a consistent body of evidence (see above), is
somewhat tentative because the intraindividual correlation between gain
in leg weight and attenuation of postural vasoconstrictor responses was
not statistically significant. However, a correlation would not
establish cause-effect relations nor could it exclude the influence of
third unknown variables. Therefore additional mechanistic studies
are needed to delineate more exactly the role of postural vasomotion
and dependent edema during CCBs.
In agreement with previous observations obtained with drugs belonging
to similar pharmacological classes,11 enalapril restrained
fluid extravasation by amlodipine in that weight increments during
combined treatment at 10 mg UID were similar to those induced by CCB
monotherapy at one half that dosage. This clinically favorable property
compounds the additive antihypertensive effect of association therapy
with CCBs and ACEIs, documented again and again since the first
descriptions.29 Besides inhibiting angiotensin
II production, ACEIs may increase bradykinin levels, enhance
the release of prostaglandins, and depress
-adrenergic
responsiveness.30 None of those biological systems,
however, appear to maintain or assist the postural increase in skin
precapillary resistance associated with lowering one extremity below
heart level, because enalapril did not alter the postural reflex
control of skin vascular resistance nor did it interfere with the
antagonistic effect of amlodipine. As a consequence, the
attenuation of dependent fluid extravasation by the ACEI probably
occurred by different biological mechanisms. Perhaps a complex
interplay might take place at the microcirculatory level between more
effective inhibition of precapillary resistance vessels by the
CCB31 and preferential venodilatation by the
ACEI,32 with a resulting limitation of the rise in
capillary pressure. We have, however, no data in favor of or against
this possibility.
In conclusion, amlodipine, a dihydropyridine CCB, increased intravascular fluid filtration to the extravascular compartment through mechanisms independent of interference with postural reflex skin vasoconstriction; however, effective skin blood flow autoregulation may have limited excessive fluid filtration. Pretreatment with enalapril, an ACEI, attenuated dependent fluid extravasation by amlodipine without modifying its antagonism for postural vasoconstriction.
| Acknowledgments |
|---|
Received August 3, 1999; first decision August 24, 1999; accepted September 27, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. Jordan, S. Engeli, S. W. Boye, S. Le Breton, and D. L. Keefe Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension Hypertension, May 1, 2007; 49(5): 1047 - 1055. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Weir, K. C. Ferdinand, J. M. Flack, K. A. Jamerson, W. Daley, S. Zelenkofske, and for the AADVANCE Investigators A Noninferiority Comparison of Valsartan/Hydrochlorothiazide Combination Versus Amlodipine in Black Hypertensives Hypertension, September 1, 2005; 46(3): 508 - 513. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Blankfield Fluid Matters in Choosing Antihypertensive Therapy: A Hypothesis That the Data Speak Volumes J Am Board Fam Med, March 1, 2005; 18(2): 113 - 124. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |